MedTrace Logo

Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia

NCT04652349 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 279

Last updated 2021-03-05

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and clinical efficacy of HGP1910 and HCP1903 in patients with primary hypercholesterolemia

Conditions

  • Primary Hypercholesterolemia

Interventions

DRUG

HGP1910

Take it once daily for 8 weeks orally.

DRUG

HCP1903

Take it once daily for 8 weeks orally.

DRUG

HGP1909

Take it once daily for 8 weeks orally.

DRUG

HGP1911

Take it once daily for 8 weeks orally.

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-06
Primary Completion
2020-12-17
Completion
2021-01-14

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04652349 on ClinicalTrials.gov